PM 060184

Drug Profile

PM 060184

Alternative Names: PM-184; PM-60184; PM060184

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmaMar
  • Class Antineoplastics
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer
  • Phase I Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Monotherapy) in USA (IV, Infusion)
  • 09 Dec 2015 Phase-II clinical trials in Breast cancer (Second-line therapy or greater, Late-stage disease) in Spain (IV) (EudraCT2015-002395-24)
  • 01 Aug 2015 PharmaMar completes a phase I trial in Solid tumours (Monotherapy) in USA (NCT01299636)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top